Why This Titanium Explorer Caught Rio Tinto’s Eye

As U.S. defense spending crosses $1 trillion, drones, hypersonics, and next-gen aerospace are taking center stage.

Behind them? Titanium - lightweight, nearly as strong as steel, and essential to the F-35 Raptor, missile systems, and long-endurance UAVs. Yet the U.S. imports 91% of it... mostly from China, Russia, and Kazakhstan.

That's why one new discovery in Canada is attracting serious attention. It's targeting a massive titanium-vanadium system with grades and scale that rival the largest in the world - and it's just 10 km from deepwater shipping, skilled workforce, and nearby hydroelectric power.

A recent geophysics survey returned magnetometer readings so intense they maxed out the equipment.

With a large oxide layering thickness, a near-monomineralic Vanadiferous Titanomagnetite (VTM) composition, and extensive mineral tenures, the Radar Titanium Project shows the potential to become a globally significant VTM project.

This could be one of North America's most strategically important new sources of titanium - and it's still flying under the radar.

Read the full story here.

Capital Trends

Just For You

Global Medical: This REIT Just Got a 30% Price Target

Written by Sam Quirke. Published 10/20/2025.

Key Points

Global Medical REIT’s multi-year downtrend may finally be ending.
Fresh analyst upgrades are indicating as much as a nearly 30% upside from current levels.
A juicy 9.3% dividend yield adds to an increasingly attractive risk/reward setup.

Real Estate Investment Trusts, or REITs, are often a favorite among income investors. They offer regular dividends, provide easy exposure to tangible assets, and can serve as a natural hedge against inflation. Within that universe, Global Medical REIT Inc. (NYSE: GMRE) stands out as a niche player focused on healthcare properties. Its portfolio includes medical office buildings, outpatient facilities, and specialty care centers—all backed by long-term leases and stable tenants.

Frustratingly for investors, however, while this brick-and-mortar stability looks good on paper, it hasn't helped Global Medical much in recent years. Its shares have been in a persistent decline since December 2021, losing more than 60% of their value. As we'll see below, several factors contributed to this, and the stock hit fresh all-time lows earlier this month.

Your account status (Ad)

Your $200 MarketBeat account credit expires in less than twelve hours. Upgrade to MarketBeat All Access today and save $200 on your 2025-2026 MarketBeat premium subscription.

Claim My Discount

But after years of relentless selling, there are finally signs of a bottom forming. With several analysts starting to turn bullish and the technical picture improving, there are reasons to think Global Medical's long-awaited recovery may be taking shape. Let's take a closer look.

A Brutal Downtrend, But a Clear Floor Emerging

Much of the stock's decline can be traced to higher interest rates and investor skepticism toward debt-heavy real estate names, which made bears particularly focused on Global Medical. It didn't help that leadership trimmed the dividend by 29% earlier this year, which shook investor confidence just as the stock was consolidating.

Still, the stock may have found a floor. The $30 level has emerged as a critical line of support; it's where sellers ran out of steam last May, and buyers have been stepping in again. Over the past week, shares have bounced sharply off the $30 level, suggesting institutional investors may be quietly building positions.

Momentum indicators are also beginning to favor the bulls. The RSI has rebounded from deeply oversold territory, and the stock's MACD is on the verge of a bullish crossover. After nearly four years of downward pressure, Global Medical's chart shows early signs of putting in a low — for those on the sidelines, that presents an interesting entry opportunity.

Analysts Are Turning Bullish Again

An ongoing shift in Wall Street sentiment is strengthening that case. Earlier this week, Citizens JMP upgraded its rating on Global Medical from Market Perform to Outperform while setting a new price target of $40. From where the stock closed on Wednesday evening, that implies upside of nearly 30%.

Their upgrade echoed Zacks Research, which raised its rating on Global Medical to Strong Buy last month, reflecting growing optimism across the analyst community. There appears to be a view that much of the downside has been absorbed and that the company's improving balance sheet and a more supportive macro backdrop are reasons to be constructive.

Indeed, the broader environment for REITs is beginning to improve. Expectations of interest-rate cuts relieve pressure on yield-sensitive stocks like Global Medical, and the company's recently announced $50 million share repurchase program provides additional support.

The company's new CEO has emphasized deleveraging, signaling management's intent to address issues that have weighed on shareholders.

For investors considering exposure around the $30 mark, the company's 9.31% dividend yield is notably attractive.

That yield offers a meaningful income stream even if the recovery takes time.

Risks Remain, But The Setup Is Compelling

That said, risks remain. Global Medical is highly sensitive to interest-rate movements, and while the Fed appears to be entering a softening cycle, the timing of rate cuts is uncertain. The company also faces lingering skepticism from investors who watched the shares continue to sell off while the broader market rallied this past summer.

Still, the risk/reward profile looks favorable at these levels. After a roughly 60% peak-to-trough decline, much of the bad news has likely been priced in, and recent analyst upgrades indicate sentiment is starting to shift.

If shares can hold above $30 through the rest of October, it would strengthen the case that a durable base has formed. From there, the technicals and analyst targets suggest room for a meaningful rebound into year-end.

This email communication is a paid advertisement for Capital Trends, a third-party advertiser of MarketBeat. Why did I get this email message?.

This message is a paid advertisement for Sage Metals (CSE:SAGA OTC:SAGMF) from Capital Trends and Think Ink Marketing. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $2,750. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Capital Trends or Think Ink Marketing. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Sage Metals (CSE:SAGA OTC:SAGMF) on Think Ink Marketing' website for additional information about the relationship between Think Ink Marketing and Sage Metals (CSE:SAGA OTC:SAGMF).

If you need assistance with your account, please email our South Dakota based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

Copyright 2006-2025 MarketBeat Media, LLC.
345 N Reid Pl., Suite 620, Sioux Falls, South Dakota 57103. U.S.A..

Further Reading: $1 'Superhuman' Stock (From Immersed)